Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
Abstract Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy,...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-03-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12933-020-01010-x |
| _version_ | 1818839266714714112 |
|---|---|
| author | Dario Giugliano Luca De Nicola Maria Ida Maiorino Giuseppe Bellastella Carlo Garofalo Paolo Chiodini Antonio Ceriello Katherine Esposito |
| author_facet | Dario Giugliano Luca De Nicola Maria Ida Maiorino Giuseppe Bellastella Carlo Garofalo Paolo Chiodini Antonio Ceriello Katherine Esposito |
| author_sort | Dario Giugliano |
| collection | DOAJ |
| description | Abstract Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy, this SGLT-2 inhibitors effect is unique because, at variance with other components of cardiorenal protection, MACE prevention does not appear to be a class effect. Here, we present meta-analysis of the four key CVOTs indicating a major role of renal function in determining the extent of MACE prevention, with the benefit increasing in more severe kidney disease, that is, a high-risk condition where effectiveness of the traditional approach with statins is reduced. |
| first_indexed | 2024-12-19T03:51:34Z |
| format | Article |
| id | doaj.art-5d306fe2fcd346dd9cf9f4b9461f6c2b |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-12-19T03:51:34Z |
| publishDate | 2020-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-5d306fe2fcd346dd9cf9f4b9461f6c2b2022-12-21T20:36:58ZengBMCCardiovascular Diabetology1475-28402020-03-011911610.1186/s12933-020-01010-xPreventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidneyDario Giugliano0Luca De Nicola1Maria Ida Maiorino2Giuseppe Bellastella3Carlo Garofalo4Paolo Chiodini5Antonio Ceriello6Katherine Esposito7Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, Università della Campania L. VanvitelliNephrology Unit, Department of Advanced Medical and Surgical Sciences, Università della Campania L. VanvitelliDiabetes Unit, Department of Advanced Medical and Surgical Sciences, Università della Campania L. VanvitelliDivision of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, Università della Campania L. VanvitelliNephrology Unit, Department of Advanced Medical and Surgical Sciences, Università della Campania L. VanvitelliMedical Statistics Unit, Università della Campania Luigi VanvitelliDepartment of Cardiovascular and Metabolic Diseases, IRCCS MultiMedicaDiabetes Unit, Department of Advanced Medical and Surgical Sciences, Università della Campania L. VanvitelliAbstract Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy, this SGLT-2 inhibitors effect is unique because, at variance with other components of cardiorenal protection, MACE prevention does not appear to be a class effect. Here, we present meta-analysis of the four key CVOTs indicating a major role of renal function in determining the extent of MACE prevention, with the benefit increasing in more severe kidney disease, that is, a high-risk condition where effectiveness of the traditional approach with statins is reduced.http://link.springer.com/article/10.1186/s12933-020-01010-xSGLT-2 inhibitorsType 2 diabetesMACEDiabetic kidney diseaseStatin therapy |
| spellingShingle | Dario Giugliano Luca De Nicola Maria Ida Maiorino Giuseppe Bellastella Carlo Garofalo Paolo Chiodini Antonio Ceriello Katherine Esposito Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney Cardiovascular Diabetology SGLT-2 inhibitors Type 2 diabetes MACE Diabetic kidney disease Statin therapy |
| title | Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney |
| title_full | Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney |
| title_fullStr | Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney |
| title_full_unstemmed | Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney |
| title_short | Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney |
| title_sort | preventing major adverse cardiovascular events by sglt 2 inhibition in patients with type 2 diabetes the role of kidney |
| topic | SGLT-2 inhibitors Type 2 diabetes MACE Diabetic kidney disease Statin therapy |
| url | http://link.springer.com/article/10.1186/s12933-020-01010-x |
| work_keys_str_mv | AT dariogiugliano preventingmajoradversecardiovasculareventsbysglt2inhibitioninpatientswithtype2diabetestheroleofkidney AT lucadenicola preventingmajoradversecardiovasculareventsbysglt2inhibitioninpatientswithtype2diabetestheroleofkidney AT mariaidamaiorino preventingmajoradversecardiovasculareventsbysglt2inhibitioninpatientswithtype2diabetestheroleofkidney AT giuseppebellastella preventingmajoradversecardiovasculareventsbysglt2inhibitioninpatientswithtype2diabetestheroleofkidney AT carlogarofalo preventingmajoradversecardiovasculareventsbysglt2inhibitioninpatientswithtype2diabetestheroleofkidney AT paolochiodini preventingmajoradversecardiovasculareventsbysglt2inhibitioninpatientswithtype2diabetestheroleofkidney AT antonioceriello preventingmajoradversecardiovasculareventsbysglt2inhibitioninpatientswithtype2diabetestheroleofkidney AT katherineesposito preventingmajoradversecardiovasculareventsbysglt2inhibitioninpatientswithtype2diabetestheroleofkidney |